Patient characteristics at transformation
| . | AML (n = 26), n (%) . | MDS (n = 28), n (%) . |
|---|---|---|
| Karyotype | ||
| Favorable* | 0 | |
| Intermediate* | 10 (38) | |
| Unfavorable* | 12 (46) | |
| Failure | 4 (15) | |
| Good† | 5 (18) | |
| Intermediate† | 4 (14) | |
| Poor† | 15 (54) | |
| Failure | 4 (14) | |
| WHO classification | ||
| Marrow blasts > 30% | 17 (65) | |
| Marrow blasts 20%-30% (RAEB-t) | 9 (35) | |
| RAEB-1 | 9 (32) | |
| RAEB-2 | 19 (68) | |
| IPSS | ||
| Low | 0 | |
| Intermediate 1 | 2 (7) | |
| Intermediate 2 | 12 (43) | |
| High | 10 (36) | |
| NE‡ | 4 (14) |
| . | AML (n = 26), n (%) . | MDS (n = 28), n (%) . |
|---|---|---|
| Karyotype | ||
| Favorable* | 0 | |
| Intermediate* | 10 (38) | |
| Unfavorable* | 12 (46) | |
| Failure | 4 (15) | |
| Good† | 5 (18) | |
| Intermediate† | 4 (14) | |
| Poor† | 15 (54) | |
| Failure | 4 (14) | |
| WHO classification | ||
| Marrow blasts > 30% | 17 (65) | |
| Marrow blasts 20%-30% (RAEB-t) | 9 (35) | |
| RAEB-1 | 9 (32) | |
| RAEB-2 | 19 (68) | |
| IPSS | ||
| Low | 0 | |
| Intermediate 1 | 2 (7) | |
| Intermediate 2 | 12 (43) | |
| High | 10 (36) | |
| NE‡ | 4 (14) |
AML indicates acute myeloid leukemia; MDS, myelodysplastic syndrome; WHO, World Health Organization; RAEB-t, refractory anemia with excess blasts in transformation; RAEB-1, refractory anemia with excess blasts 1; RAEB-2, refractory anemia with excess blasts 2; and NE, not evaluable.
Medical Research Council classification.
International Prognostic Scoring System classification.
Cytogenetic failure.